Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 4/2014

01-04-2014 | Research Article

The Val158Met polymorphism in the COMT gene is associated with increased cancer risks in Chinese population

Authors: Can Tian, Liping Liu, Xiaohong Yang, Hui Wu, Quchang Ouyang

Published in: Tumor Biology | Issue 4/2014

Login to get access

Abstract

The Val158Met polymorphism in the COMT gene may affect the DNA repair pathways and be associated with the risk of cancer in Chinese population. However, the results of previous studies are inconsistent. The objective of this study was to investigate the association between the Val158Met polymorphism in the COMT gene and the risk of cancer for Chinese population by meta-analysis. We searched PubMed, Embase, CNKI, Weipu, and Wanfang databases, and the last search was updated on Sep. 26, 2013. Statistical analysis was performed using the Revman4.2 and Stata10.0 software. A total of 18 case–control studies concerning 5034 case and 6234 controls were included. In the total analysis, the results suggested a significant association between the Val158Met polymorphism in the COMT gene and the cancer risk in Chinese population: OR = 1.34, 95 %CI = 1.04–1.73, and P = 0.03 for AA vs. AG + GG; OR = 1.39, 95 %CI = 1.06–1.82, and P = 0.02; OR = 1.13, 95 %CI = 1.01–1.27, and P = 0.04. In the subgroup analysis by cancer types, significant association was found in the breast cancer and esophageal squamous cell carcinoma. The current meta-analysis confirmed that the Val158Met polymorphism in the COMT gene may be a risk factor for cancer in Chinese population. In the future, more case–control studies are needed to validate our results.
Literature
1.
Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer. 2001;37:4–66.CrossRef
2.
Lin SC, Chou YC, Wu MH, Wu CC, Lin WY, Yu CP, et al. Genetic variants of myeloperoxidase and catechol-O-methyltransferase and breast cancer risk. Eur J Cancer Prev. 2005;14:257–61.PubMedCrossRef
3.
Shibuta K, Mori M, Haraguchi M, Yoshikawa K, Ueo H, Akiyoshi T. Association between restriction fragment length polymorphism of the L-myc gene and susceptibility to gastric cancer. Br J Surg. 1998;85:681–4.PubMedCrossRef
4.
Nomura M, Shigematsu H, Li L, Suzuki M, Takahashi T, Estess P, et al. Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers. PLoS Med. 2007;4:e125.PubMedCentralPubMedCrossRef
5.
El-Omar EM, Ng MT, Hold GL. Polymorphisms in toll-like receptor genes and risk of cancer. Oncogene. 2008;27:244–52.PubMedCrossRef
6.
Sanders AR, Rusu I, Duan J, Vander Molen JE, Hou C, Schwab SG, et al. Haplotypic association spanning the 22q11.21 genes COMT and ARVCF with schizophrenia. Mol Psychiatry. 2004;10:353–65.CrossRef
7.
Zhang YG, Li XB, Zhang J, Huang J, He C, Tian C, et al. The I/D polymorphism of angiotensin-converting enzyme gene and asthma risk: a meta-analysis. Allergy. 2011;66:197–205.PubMedCrossRef
8.
Cheng TC, Chen ST, Huang CS, Fu YP, Yu JC, Cheng CW, et al. Breast cancer risk associated with genotype polymorphism of the catechol estrogen-metabolizing genes: a multigenic study on cancer susceptibility. Int J Cancer. 2005;113:345–53.PubMedCrossRef
9.
Fan Y, Feng YM, Wang LM, Wang Y, Fu L. The relationship between catechol-O-methyltransferase (COMT) polymorphisms and the development of breast cancer. Zhong Guo Zhong Liu Lin Chuang (Chinese). 2007;34:430–3.
10.
Hu Z, Song CG, Lu JS, Luo JM, Shen ZZ, Huang W, et al. A multigenic study on breast cancer risk associated with genetic polymorphisms of ER Alpha, COMT and CYP19 gene in BRCA1/BRCA2 negative Shanghai women with early onset breast cancer or affected relatives. J Cancer Res Clin Oncol. 2007;133:969–78.PubMedCrossRef
11.
Huang CG, Liu T, Lv GD, Liu Q, Feng JG, Zheng ST, et al. The association analysis of catechol-O-methyltransferase gene Val158Met polymorphisms with esophageal squamous cell carcinoma in Yili Prefecture of Xinjiang. Zhong Hua Xiao Hua Za Zhi (Chinese). 2011;31:6–10.
12.
Li J, Liu K, Jiang SF, Cheng HY, Yuan JX, Zhu FL, et al. A case–control study of the relationship among environmental factors, COMT genetic polymorphisms and breast cancer. Hu Bei Wen Li Xue Yuan Xue Bao (Chinese). 2013;34:82–8.
13.
Li L, Li FX, Zhang N, Du YF, Cheng JX. Association of gene polymorphism in cytochrome P450 1b1 and COMT, with the expression of mRNA and susceptibility to endometrial cancer. He Bei Yi Ke Da Xue Xue Bao (Chinese). 2010;31:1433–7.
14.
Lim WY, Chen Y, Chuah KL, Eng P, Leong SS, Lim E, et al. Female reproductive factors, gene polymorphisms in the estrogen metabolism pathway, and risk of lung cancer in Chinese women. Am J Epidemiol. 2012;175:492–503.PubMedCrossRef
15.
Tan W, Qi J, Xing DY, Miao XP, Pan KF, Zhang L, et al. Relation between single nucleotide polymorphism in estrogen-metabolizing genes COMT, CYP17 and breast cancer risk among Chinese women. Zhong Hua Zhong Liu Za Zhi (Chinese). 2003;25:453–6.
16.
Wang Q, Li H, Tao P, Wang YP, Yuan P, Yang CX, et al. Soy isoflavones, CYP1a1, CYP1b1, and COMT polymorphisms, and breast cancer: a case–control study in southwestern China. DNA Cell Biol. 2011;30:585–95.PubMedCrossRef
17.
Wen WQ, Cai QY, Shu XO, Cheng JR, Parl F, Pierce L, et al. Cytochrome P450 1b1 and catechol-O-methyltransferase genetic polymorphisms and breast cancer risk in Chinese women: results from the shanghai breast cancer study and a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2005;14:329–35.PubMedCrossRef
18.
Wu AH, Tseng CC, Van Den Berg D, Mimi CY. Tea intake, COMT genotype, and breast cancer in Asian-American women. Cancer Res. 2003;63:7526–9.PubMed
19.
Xu YJ, Ge YL, Zhang JY, Li FN, Zheng Z. Polymorphism of COMT, p21 and NuMA in sporadic breast cancer. Zhong Hua Lin Chuang Yi Shi Za Zhi (Chinese). 2010;4:591–6.
20.
Yin PH, Lee HC, Chau GY, Liu TY, Liu HC, Lui WY, et al. Polymorphisms of estrogen-metabolizing genes and risk of hepatocellular carcinoma in Taiwan females. Cancer Lett. 2004;212:195–201.PubMedCrossRef
21.
Yuan XY, Zhou GQ, Zhai Y, Xie WM, Cui Y, Cao J, et al. Lack of association between the functional polymorphisms in the estrogen-metabolizing genes and risk for hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev. 2008;17:3621–7.PubMedCrossRef
22.
Zhang YJ, Hua S, Zhang AQ, Kong XM, Jiang CM, Deng DH, et al. Association between polymorphisms in COMT, PLCH1, and CYP17a1, and non-small-cell lung cancer risk in Chinese nonsmokers. Clin Lung Cancer. 2013;14:45–9.PubMedCrossRef
23.
Zhou YH. Association between polymorphisms of estrogen receptors & estrogen motablic enzymes and susceptibility to colorectal cancer, 2009.
24.
Zhu MM: The relationship between polymorphisms in estrogen-metabolizing genes CYP17, COMT and risk of cirrhosis of hepatocellular carcinoma in Hepatitis b infected patients, 2008.
25.
Zhao XM, Zhao YF, Zhao ZY, Zhao WJ, Tang XL, Xie MQ. Exploration of the approaches of analyzing the genetic polymorphism of catechol-O-methyltransferase. Zhong Guo Shi Yan Zhen Duan Xue (Chinese). 2012;16:2021–4.
Metadata
Title
The Val158Met polymorphism in the COMT gene is associated with increased cancer risks in Chinese population
Authors
Can Tian
Liping Liu
Xiaohong Yang
Hui Wu
Quchang Ouyang
Publication date
01-04-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 4/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1387-6

Other articles of this Issue 4/2014

Tumor Biology 4/2014 Go to the issue

Research Article

The upregulation of programmed death 1 on peripheral blood T cells of glioma is correlated with disease progression

Research Article

STAG2 expression in oral cancer and potentially malignant lesions

Research Article

Clinical significance of serum insulin-like growth factor-1 (IGF-1) and insulinlike growth factor binding protein-3 (IGFBP-3) in patients with epithelial ovarian cancer

Research Article

Allergic conditions reduce the risk of glioma: a meta-analysis based on 128,936 subjects

Research Article

Cytochrome b5 reductase 2 is a novel candidate tumor suppressor gene frequently inactivated by promoter hypermethylation in human nasopharyngeal carcinoma

Research Article

N-acetyltransferase 2 genetic variants confer the susceptibility to head and neck carcinoma: evidence from 23 case–control studies
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits